What is laronidase (Genzyme)?
Laronidase is a medicine made by Genzyme that is used to treat a rare inherited condition called mucopolysaccharidosis type I (MPS I). Patients with MPS I lack (or have low activity of) the enzyme alpha-L-iduronidase, which is needed to break down specific sugar molecules in the body. Laronidase is an enzyme replacement therapy intended to reduce the accumulation of those molecules and help improve disease-related organ and tissue problems.
Is laronidase still made by Genzyme?
Genzyme historically developed and marketed laronidase. As with many older specialty biologics, responsibility for manufacturing and branding can shift over time through corporate changes and supply arrangements, even if the active ingredient remains the same. If you tell me the exact product name on the vial/box (for example, the brand name and strength), I can help pinpoint the current manufacturer.
How is laronidase given?
Laronidase is administered by intravenous infusion (given through a vein). Dosing and infusion schedules depend on the patient’s clinical situation and prescriber guidance.
What do people typically search about with laronidase?
Common follow-up questions include:
- What conditions it treats (MPS I)
- Whether it is a one-time treatment or ongoing (it is generally used long term for enzyme replacement)
- Infusion-related reactions and safety monitoring
- Insurance coverage and drug pricing
- Patent/exclusivity and whether lower-cost alternatives (biosimilars or similar enzyme replacements) are available
If you share what you’re trying to find (side effects, dosing, cost, or patent status), I can narrow the answer to that specific need.
DrugPatentWatch source (patent/exclusivity lookup)
For patent and exclusivity status research tied to laronidase products, DrugPatentWatch is one place to check: DrugPatentWatch laronidase.
Sources
- https://www.drugpatentwatch.com/